What is ENHERTU?

ENHERTU is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments.

It is not known if ENHERTU is safe and effective in children.

How will I receive ENHERTU?

You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider. ENHERTU is given 1 time every three weeks (21-day treatment cycle).

Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:

- have lung or breathing problems.
- have signs or symptoms of an infection.
- have or have had any heart problems.
- are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See “What is the most important information I should know about ENHERTU?”

The most common side effects of ENHERTU include:

- nausea
- feeling tired
- vomiting
- hair loss
- diarrhea
- cough
- constipation
- low white blood cell counts
- low red blood cell counts
- hair loss
- decreased appetite

ENHERTU may cause fertility problems in males, which may affect the ability to father children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of ENHERTU.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about ENHERTU that is written for healthcare professionals.

What are the ingredients in ENHERTU?

Active Ingredient: fam-trastuzumab deruxtecan-nxki.

Inactive Ingredient: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose.

Manufactured by: Daiichi Sankyo Company, Ltd.

Marketed by: Daiichi Sankyo, Inc., Basking Ridge, NJ 07920

AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

ENHERTU® is a registered trademark of Daiichi Sankyo Company, Ltd. © 2019 Daiichi Sankyo Co., Ltd.

USMG-ENH-C1-1219-r001

For more information, call 1-877-437-7763 or go to http://www.ENHERTU.com.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Issued: 12/2019